Serotonin, cerebral blood flow, and cerebral metabolic rate in geriatric major depression and normal aging

Brain Research Reviews

Volumn 30, Issue 3, 1999, Pages 250-263

  Nobler, Mitchell S ^a,b   Mann, J John ^a,b   Sackeim, Harold A ^a,b  

^a New York Stt Psychiat I   (United States)

^b Coll Phys Surgs Columbia Univ ^*  (United States)

Author keywords

Aging; Cerebral blood flow; Cerebral metabolic rate; Major depressive disorder; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; IMIPRAMINE; NORTRIPTYLINE; PAROXETINE; RADIOLIGAND; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRYPTOPHAN;

AGED; AGING; BRAIN BLOOD FLOW; BRAIN METABOLISM; DEPRESSION; HUMAN; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM;

AGED; AGING; ANIMALS; BRAIN; CEREBRAL ARTERIES; CEREBROVASCULAR CIRCULATION; DEPRESSIVE DISORDER, MAJOR; HUMANS; REFERENCE VALUES; SEROTONIN;

EID: 0032737167     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(99)00019-3     Document Type: Review

References (160)

1. 11C ]5-hydroxytryptophan in major depression: a positron emission tomography study on patients and healthy volunteers Acta Psychiatr. Scand. 83:1991;449-455.
2. Alexopoulos G.S., Meyers B.S., Young R.C., Campbell S., Silbersweig D., Charlson M. 'Vascular depression' hypothesis. Arch. Gen. Psychiatry. 54:1997;915-922.
3. Allen S.J., Benton J.S., Goodhardt M.J., Haan E.A., Sims N.R., Smith C.C., Spillane J.A., Bowen D.M., Davison A.N. Biochemical evidence of selective nerve cell damage in the normal ageing human and rat brain. J. Neurochem. 41:1983;256-265.
4. Amsterdam J.D. Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. J. Psychopharmacol. 12:1998;S99-S111.
5. Anderson I.M., Tomenson B.M. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J. Psychopharmacol. 8:1994;238-249.
6. 3H ]paroxetine binding Gerontology. 38:1992;127-132.
7. Arranz B., Eriksson A., Mellerup E., Plenge P., Marcusson J. Effect of aging in human cortical pre- and postsynaptic serotonin binding sites. Brain Res. 620:1993;163-166.
8. 3H ]-paroxetine binding in rat brain: effect of imipramine and tetrahydroacridine Life Sci. 52:1993;1767-1775.
9. Aston-Jones G., Akaoka H., Charlety P., Chouvet G. Serotonin selectively attenuates glutamate-evoked activation of noradrenergic locus coeruleus neurons. J. Neurosci. 11:1991;760-769.
10. 18F ]-setoperone during depressive illness and antidepressant treatment with clomipramine Biol. Psychiatry. 45:1999;180-186.
11. 2A receptors: influence of age and gender in healthy subjects Eur. J. Nucl. Med. 25:1998;1617-1622.
12. Baxter L., Schwartz J.M., Phelps M.E., Mazziotta J.C., Guze B.H., Selin C.E., Gerner R.H., Sumida R.M. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch. Gen. Psychiatry. 46:1989;243-250.
13. Bench C.J., Friston K., Brown R.G., Scott L.C., Frackowiak R.S., Dolan R.J. The anatomy of melancholia - focal abnormalities of cerebral blood flow in major depression. Psychol. Med. 22:1992;607-615.
14. Bharucha A.J., Satlin A. Late-life suicide: a review. Harv. Rev. Psychiatry. 5:1997;55-65.
15. Biver F., Goldman S., Delvenne V., Luxen A., De Maertelaer V., Hubain P., Mendelwicz J., Lotstra F. Frontal and parietal metabolic disturbances in unipolar depression. Biol. Psychiatry. 36:1994;381-388.
16. 2 receptor imaging in major depression: focal changes in orbito-insular cortex. Br. J. Psychiatry. 171:1997;444-448.
17. 18F ]setoperone Brain. 116:1993;497-510.
18. G. Bonvento, P. Lacombe, Serotonin and the cerebral circulation, in: J.W. Phillis (Ed.), The Regulation of Cerebral Blood Flow, CRC Press, Boca Raton, FL, 1994, pp. 97-112.
19. Bowen D.M., Najlerahim A., Procter A.W., Francis P.T., Murphy E. Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life. Proc. Natl. Acad. Sci. 86:1989;9504-9508.
20. Brunello N., Riva M., Rovescalli A., Galimberti R., Racagni G. Age-related changes in rat serotonergic and adrenergic systems and in receptor responsiveness to subchronic desipramine treatment. Pharmacol. Toxicol. 63:1988;150-155.
21. Byrum C., MacFall J., Charles H., Chitilla V., Boyko O., Upchurch L., Smith J., Rajagopalan P., Passe T., Kim D., Xanthakos S., Ranga Krishnan K. Accuracy and reproducibility of brain and tissue volumes using a magnetic resonance segmentation method. Psychiatr. Res.: Neuroimaging. 67:1996;215-234.
22. Cleare A.J., Murray R.M., O'Keane V. Assessment of serotonergic function in major depression using D-fenfluramine: relation to clinical variables and antidepressant response. Biol. Psychiatry. 44:1998;555-561.
23. Coffey C.E., Figiel G.S., Djang W.T., Weiner R.D. Subcortical hyperintensity on magnetic resonance imaging: a comparison of normal and depressed elderly subjects. Am. J. Psychiatry. 147:1990;187-189.
24. Cohen Z., Bonvento G., Lacombe P., Hamel E. Serotonin in the regulation of brain microcirculation. Prog. Neurobiol. 50:1996;335-362.
25. Cook E., Metz J., Leventhal B., Lebovitz M., Nathan M., Semerdjian S., Brown T., Cooper M. Fluoxetine effects on cerebral glucose metabolism. NeuroReport. 5:1994;1745-1748.
26. Cowen T., Thrasivoulou C. Cerebrovascular nerves in old rats show reduced accumulation of 5-hydroxytryptamine and loss of nerve fibers. Brain Res. 513:1990;237-243.
27. Cudennec A., Duverger D., Serrano A., Scatton B., MacKenzie E.T. Influence of ascending serotonergic pathways on glucose use in the conscious rat brain: II. Effects of electrical stimulation of the rostral raphe nuclei. Brain Res. 444:1988;227-246.
28. Danish University Antidepressant Group Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology. 90:1986;131-138.
29. Danish University Antidepressant Group A selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affective Disord. 18:1990;289-299.
30. Delgado P.L., Price L.H., Miller H.L., Salomon R.M., Licinio J., Krystal J.H., Heninger G.R., Charney D.S. Rapid serotonin depletion as a provocative challenge test for patients with major depression: relevance to antidepressant action and the neurobiology of depression. Psychopharmacol. Bull. 27:1991;321-330.
31. 2 receptors in depression. Psychiatr. Res.: Neuroimaging. 45:1992;227-237.
32. 1A receptor binding in the human brain postmortem: effects of age and alcohol. Brain Res. 554:1991;56-64.
33. Drevets W.C. Functional neuroimaging studies of depression: the anatomy of melancholia. Annu. Rev. Med. 49:1998;341-361.
34. Drevets W.C., Videen T.O., Price J.L., Preskorn S.H., Carmichael S.T., Raichle M.E. A functional anatomical study of unipolar depression. J. Neurosci. 12:1992;3628-3641.
35. Dunn R.T., Willis M., Kimbrell T.A., Speer A.M., Osuch E.A., Benson B., Repella J., Post R.M. Comparison of cerebral metabolism and blood flow in affective disorders. Biol. Psychiatry. 45:1999;130S.
36. Dyken M.L., Wolf P.A., Barnett H.J.M. Risk factors in stroke: a statement for physicians by the subcommittee on risk factors and stroke of the Stroke Council. Stroke. 15:1984;1105-1111.
37. Emslie G., Rush A., Weinberg W., Kowatch R.A., Hughes C.W., Carmody T., Rintelmann J. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch. Gen. Psychiatry. 54:1997;1031-1037.
38. F. Faraci, Cerebral circulation during aging, in: J.W. Phillis (Ed.), The Regulation of Cerebral Blood Flow, CRC Press, Boca Raton, FL, 1994, pp. 341-352.
39. 2 receptor agonist, on local cerebral glucose metabolism in awake rats. Brain Res. 541:1991;63-69.
40. Freo U., Soncrant T., Ricchieri G., Wozniak K., Larson D., Rapoport S. Time courses of behavioral and regional cerebral metabolic responses to different doses of meta-chlorophenylpiperazine in awake rats. Brain Res. 511:1990;209-216.
41. Friston K.J., Grasby P.M., Bench C.J., Frith C.D., Cowen P.J., Liddle P.F., Frackowiak R.S.J., Dolan R. Measuring the neuromodulatory effects of drugs in man with positron emission tomography. Neurosci. Lett. 141:1992;106-110.
42. George M.S., Ketter T.A., Post R.M. Prefrontal dysfunction in clinical depression. Depression. 2:1994;59-72.
43. Glassman A.H., Shapiro P.A. Depression and the course of coronary artery disease. Am. J. Psychiatry. 155:1998;4-11.
44. Golden R.N., Ekstrom D., Brown T., Ruegg R., Evans D., Haggerty J. Jr., Garbutt J., Pedersen C., Mason G., Browne J., Carson S. Neuroendocrine effects of intravenous clomipramine in depressed patients and healthy subjects. Am. J. Psychiatry. 149:1992;1168-1175.
45. Golden R.N., Gilmore J.H., Ekstrom R.D., Knight B., Ruegg R.G., Miller H.L., Carson S.W. The effects of age, gender, and season on serotonergic function in healthy subjects. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 20:1996;1315-1323.
46. P. Goodnick, Newer antidepressants, in: P. Goodnick (Ed.), Predictors of Treatment Response in Mood Disorders, American Psychiatric Press, Washington, DC, 1996, pp. 57-94.
47. Goodnick P., Henry J., Kumar A. Neurochemistry and paroxetine response in major depression. Biol. Psychiatry. 37:1995;417-419.
48. Goyer P.F., Semple W.E., Morris E.D., Muswick G.J., Compton B.A., Garnett M.L., Nelson D.A., Miraldi F., Schulz S.C., Meltzer H.Y. Effects of MK-212 on regional cerebral blood flow in humans. Schizophr. Res. 9:1993;199.
49. Gozlan H., Daval G., Verge D., Spampinato U., Fattaccini C., Gallissot M., el Mestikaway S., Hamon M. Aging associated changes in serotonergic and dopaminergic pre- and postsynaptic neurochemical markers in the rat brain. Neurobiol. Aging. 11:1990;437-449.
50. Grome J.J., Harper A.M. Local cerebral glucose utilisation following indoleamine- and piperazine-containing 5-hydroxytriptamine agonists. J. Neurochem. 46:1986;117-124.
51. 3H ]ketanserin binding in the human brain postmortem: effect of suicide Brain Res. 507:1990;208-215.
52. H. Grossman, G. Harris, S. Jacobson, M. Folstein, The normal elderly, in: D. Ames, E. Chui (Eds.), Neuroimaging and the Psychiatry of Late Life, Cambridge Univ. Press, Cambridge, 1997, pp. 77-99.
53. Hamilton M. A rating scale for depression. J. Neurol., Neurosurg. Psychiatry. 23:1960;56-62.
54. Hajdu M.A., McElmurry R.T., Heistad D.D., Baumbach G.L. Effects of aging on cerebral vascular responses to serotonin in rats. Am. J. Physiol. 264:1993;H2136-H2140.
55. Heiligenstein J.H., Tollefson G.D., Faries D.E. A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholia. Int. Clin. Psychopharmacol. 8:1993;247-251.
56. Hickie I., Scott E., Mitchell P., Wilhelm K., Austin M.P., Bennett B. Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression. Biol. Psychiatry. 37:1995;151-160.
57. Hommer D., Andreasen P., Rio D., Williams W., Ruttimann U., Momenan R., Zametkin A., Rawlings R., Linnoila M. Effects of m-chlorophenylpiperazine on regional brain glucose utilization: a positron emission tomographic comparison of alcoholic and control subjects. J. Neurosci. 17:1997;2796-2806.
58. Horwitz B., Duara R., Rapoport S. Age differences in intercorrelations between regional cerebral metabolic rates for glucose. Ann. Neurol. 19:1986;60-67.
59. 1A receptors during ageing: reversal by Ginkgo biloba extract (EGb 761). J. Pharm. Pharmacol. 46:1994;316-318.
60. Hyttel J., Arnt J., Sanchez C. The pharmacology of citalopram. Rev. Contemp. Pharmacother. 6:1995;271-285.
61. Itoh M., Hatazawa J., Miyazawa H., Matsu H., Meguro K., Yanai K., Kubota K., Watanuki S., Ido T., Matsuzawa T. Stability of cerebral blood flow and oxygen metabolism during normal aging. Gerontology. 36:1990;43-48.
62. 2 receptors in living human brain. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 17:1993;415-421.
63. Jacobs B.L., Azmitia E.C. Structure and function of the brain serotonin system. Physiol. Rev. 72:1992;165-229.
64. Jones J.S., Stanley B., Mann J.J., Frances A.J., Guido J.R., Traskman-Bendz L., Winchel R., Brown R.P., Stanley M. CSF 5-HIAA and HVA concentrations in elderly depressed patients who attempted suicide. Am. J. Psychiatry. 147:1990;1225-1227.
65. Kapur S., Meyer J., Wilson A., Houle S., Brown G. Modulation of cortical neuronal activity by a serotonergic agent, a PET study in humans. Brain Res. 646:1994;292-294.
66. Kegeles L.S., Mann J.J. In vivo imaging of neurotransmitter systems using radiolabeled receptor ligands. Neuropsychopharmacology. 17:1997;293-307.
67. Kelly P.A., Davis C.J., Goodwin G.M. Differential patterns of local cerebral glucose utilization in response to 5-hydroxytryptamine agonists. Neuroscience. 25:1988;907-915.
68. Krishnan K.R., Hays J.C., Blazer D.G. MRI-defined vascular depression. Am. J. Psychiatry. 154:1997;497-501.
69. W. Kuchinsky, Coupling of blood flow and metabolism in the brain in: J.W. Phillis (Ed.), The Regulation of Cerebral Blood Flow, CRC Press, Boca Raton, FL, 1993, pp 269-280.
70. Kuikka J., Tiihonen J., Bergstrom K., Karhu J., Hartikainen P., Viinamaki H., Lansimies E., Lehtonen J., Hakola P. Imaging of serotonin and dopamine transporters in the living human brain. Eur. J. Nucl. Med. 22:1995;346-350.
71. Kumar A., Newberg A., Alavi A., Berlin J., Smith R., Reivich M. Regional cerebral glucose metabolism in late-life depression and Alzheimer disease: a preliminary positron emission tomography study. Proc. Natl. Acad. Sci. 90:1993;7019-7023.
72. Lauritzen L., Odgaard K., Clemmesen L., Lunde M., Ohrstrom J., Black C., Bech P. Relapse prevention by means of paroxetine in ECT-treated patients with major depression, a comparison with imipramine and placebo in medium-term continuation therapy. Acta Psychiatr. Scand. 94:1996;241-251.
73. Lawlor B., Sunderland T., Hill J., Mellow A., Molchan S., Mueller E., Jacobsen F., Murphy D. Evidence for a decline with age in behavioral responsivity to the serotonin agonist m-chlorophenylpiperazine, in healthy human subjects. Psychiatry Res. 29:1989;1-10.
74. 3H ] paroxetine, in controls and depressed patients before and after treatment with fluoxetine or lofepramine Psychopharmacology. 115:1994;261-264.
75. Lerer B., Gillon D., Lichtenberg P., Gorfine M., Gelfin Y., Shapira A. Interrelationship of age, depression, and central serotonergic function: evidence from fenfluramine challenge studies. Int. Psychogeriatr. 8:1996;83-102.
76. Lesser I.M., Mena I., Boone K.B., Miller B.L., Mehringer C.M., Wohl M. Reduction of cerebral blood flow in older depressed patients. Arch. Gen. Psychiatry. 51:1994;677-686.
77. Lestra C., d'Amato T., Ghaemmaghami C., Perret-Liaudet A., Broyer M., Renaud B., Dalery J., Chamba G. Biological parameters in major depression: effects of paroxetine, viloxazine, moclobemide, and electroconvulsive therapy, relation to early clinical outcome. Biol. Psychiatry. 44:1998;274-280.
78. M. Maes, H. Meltzer, The serotonin hypothesis of depression, in: F. Bloom, D. Kupfer (Eds.), Psychopharmacology: The Fourth Generation of Progress, Raven Press, New York, 1995, pp. 933-944.
79. 123I ]-2β-(4-iodophenyl)tropane and single photon emission computed tomography Biol. Psychiatry. 44:1998;1090-1098.
80. Malone K.M., Thase M.E., Mieczkowski T., Myers J.E., Stull S.D., Cooper T.B., Mann J.J. Fenfluramine challenge test as a predictor of outcome in major depression. Psychopharmacol. Bull. 29:1993;155-161.
81. Mann J.J. The neurobiology of suicide. Nat. Med. 4:1998;25-30.
82. Mann J.J., Malone K.M., Diehl D.J., Perel J., Cooper T.B., Mintun M.A. Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. Am. J. Psychiatry. 153:1996;174-182.
83. Mann J.J., Malone K.M., Diehl D.J., Perel J., Nichols T.E., Mintun M.A. Positron emission tomographic imaging of serotonin activation effects on prefrontal cortex in healthy volunteers. J. Cereb. Blood Flow Metab. 16:1996;418-426.
84. Mann J.J., Mc Bride P.A., Malone K.M., DeMeo M., Keilp J. Blunted serotonergic responsivity in depressed inpatients. Neuropsychopharmacology. 13:1995;53-64.
85. J.J. Mann, C. Petito, M. Stanley, P.A. McBride, J. Chin, A. Philogene, Amine receptor binding and monoamine oxidase activity in postmortem human brain tissue: effect of age, gender and postmortem delay, in: G.D. Burrows, T.R. Norman, L. Dennerstein (Eds.), Clinical and Pharmacological Studies in Psychiatric Disorders, John Libbey, London, 1985, pp. 37-39.
86. Marchal G., Rioux P., Petit-Taboue M., Sette G., Travere J., le Poec C., Courtheoux P., Derlon J., Baron J. Regional cerebral oxygen consumption, blood flow, and blood volume in healthy human aging. Arch. Neurol. 49:1992;1013-1020.
87. 3H ]imipramine binding of protein nature in the human brain: II. Effect of normal aging and dementia disorders Brain Res. 425:1987;137-145.
88. Marcusson J.O., Morgan D.G., Winblad B., Finch C.E. Serotonin-2 binding sites in human frontal cortex and hippocampus. Selective loss of S-2A sites with age. Brain Res. 311:1984;51-56.
89. Marcusson J.O., Oreland L., Winblad B. Effects of age on human brain serotonin (S-1) binding sites. J. Neurochem. 43:1984;1699-1705.
90. Martin A.J., Friston K.J., Colebatch J.G., Frackowiak R.S. Decreases in regional cerebral blood flow with normal aging. J. Cereb. Blood Flow Metab. 11:1991;684-689.
91. 2 serotonin receptors after stroke: lateralized changes and relationship to depression. Am. J. Psychiatry. 145:1998;937-943.
92. Mayhan W.G., Faraci F.M., Baumbach G.L., Heistad D.D. Effects of aging on responses of cerebral arterioles. Am. J. Physiol. 258:1990;H1138-H1143.
93. 1A receptor activation. Brain Res. 555:1991;159-163.
94. McBride P.A., Tierney H., DeMeo M., Chen J.S., Mann J.J. Effects of age and gender on CNS serotonergic responsivity in normal adults. Biol. Psychiatry. 27:1990;1143-1155.
95. J. McCulloch, The physiology and regulation of cerebral blood flow, in: S. Knezevic, V.A. Maximilian, Z. Mubrin, I. Prohovnik, J. Wade (Eds.), Handbook of Regional Cerebral Blood Flow, Erlbaum, Hillsdale, NJ, 1988, pp. 1-24.
96. McEntee W.J., Crook T.H. Serotonin, memory, and the aging brain. Psychopharmacology. 103:1991;143-149.
97. Meek J.L., Bertilsson L., Cheney D.L., Zsilla G., Costa E. Aging-induced changes in acetylcholine and serotonin content of discrete brain nuclei. J. Gerontol. 32:1977;129-131.
98. Meltzer C.C., Leal J.P., Mayberg H.S., Wagner H.N. Jr., Frost J.J. Correction of PET data for partial volume effects in human cerebral cortex by MR imaging. J. Comput. Assist. Tomogr. 14:1990;561-570.
99. Meltzer C.C., Price J., Mathis C.A., Greer P.J., Houck P.R., Lopresti B., Ben-Elizer D., Cantwell M.C., DeKosky S.T., Reynolds C.F. [F-18] Altanserin binding to serotonin (5HT-2A) receptors in late-life depression and Alzheimer's disease. Biol. Psychiatry. 45:1999;61s.
100. 2A receptors in late-life depression J. Cereb. Blood Flow Metab. 17:1997;S626.
101. Meltzer C.C., Smith G., DeKosky S.T., Pollock B.G., Mathis C.A., Moore R.Y., Kupfer D.J., Reynolds C.F. III Serotonin in aging, late-life depression, and Alzheimer's disease: the emerging role of functional imaging. Neuropsychopharmacology. 18:1998;407-430.
102. 18F ]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction Brain Res. 813:1998;164-171.
103. Meltzer C.C., Zubieta J.K., Brandt J., Tune L.E., Mayberg H.S., Frost J.J. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology. 47:1996;454-461.
104. 18F ]setoperone PET imaging study Am. J. Psychiatry. 156:1999;1029-1034.
105. 20 PET study in humans Neurosci. Lett. 207:1996;25-28.
106. 2O PET response to intravenous D-fenfluramine Am. J. Psychiatry. 155:1998;141-146.
107. 3 antagonist ondansetron: a 2-deoxyglucose autoradiographic study in the rat. Brain Res. 538:1991;289-294.
108. Mitchell P.B., Smyth G. Endocrine and amine responses to D,L-fenfluramine in normal subjects. Psychiatry Res. 39:1991;141-153.
109. Moeller J.R., Eidelberg D. Divergent expression of regional metabolic topographies in Parkinson's disease and normal aging. Brain. 120:1997;197-206.
110. Moeller J.R., Ishikawa T., Dhawan V., Spetsieris P., Mandel F., Alexander G.E., Grady C., Pietrini P., Eidelberg D. The metabolic topography of normal aging. J. Cereb. Blood Flow Metab. 16:1996;385-398.
111. Moeller J.R., Strother S.C., Sidtis J.J., Rottenberg D.A. Scaled subprofile model: a statistical approach to the analysis of functional patterns in positron emission tomographic data. J. Cereb. Blood Flow Metab. 7:1987;649-658.
112. Morgan D.G. The dopamine and serotonin systems during aging in human and rodent brain. A brief review. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 11:1987;153-157.
113. Müller-Gärtner H.W., Links J.M., Prince J.L., Bryan R.N., McVeigh E., Leal J.P., Davatzikos C., Frost J.J. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J. Cereb. Blood Flow Metab. 12:1992;571-583.
114. Musselman D.L., Evans D.L., Nemeroff C.B. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch. Gen. Psychiatry. 55:1998;580-592.
115. Nishimura A., Ueda S., Takeuchi Y., Matsushita H., Sawada T., Kawata M. Vulnerability to aging in the rat serotonergic system. Acta Neuropathol. 96:1998;581-595.
116. M.S. Nobler, G.H. Pelton, H.A. Sackeim, Cerebral blood flow and metabolism in late-life depression and dementia, J. Geriatr. Psychiatry Neurol., in press.
117. Nobler M.S., Roose S.P. Differential response to antidepressants in melancholic and severe depression. Psychiatric Ann. 28:1998;84-88.
118. M.S. Nobler, S.P. Roose, I. Prohovnik, J.R. Moeller, J. Louie, R.L. Van Heertum, H.A. Sackeim, Regional cerebral blood flow in mood disorders: V. Effects of antidepressant medication in late-life depression, submitted for publication.
119. 1A receptor binding sites in rat cortex, hippocampus and cholinergic basal forebrain nuclei during aging. J. Chem. Neuroanat. 13:1997;53-61.
120. Owen F., Chambers D.R., Cooper S.J., Crow T.J., Johnson J.A., Lofthouse R., Poulter M. Serotonergic mechanisms in brains of suicide victims. Brain Res. 362:1986;185-188.
121. Palego L., Marazziti D., Rossi A., Giannaccini G., Naccarato A.G., Lucacchini A., Cassano G.B. Apparent absence of aging and gender effects on serotonin 1A receptors in human neocortex and hippocampus. Brain Res. 758:1997;26-32.
122. Park S.B., Williamson D.J., Cowen P.J. Do the endocrine and subjective effects of D-fenfluramine predict response to selective serotonin reuptake inhibitors? Int. Clin. Psychopharmacol. 10:1995;215-220.
123. Perez V., Bel N., Celada P., Ortiz J., Alvarez E., Artigas F. Relationship between blood serotonergic variables, melancholic traits, and response to antidepressant treatments. J. Clin. Psychopharmacol. 18:1998;222-230.
124. Perry P.J. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J. Affective Disord. 39:1996;1-6.
125. Petit-Taboue M.C., Landeau B., Desson J.F., Desgranges B., Baron J.C. Effects of healthy aging on the regional cerebral metabolic rate of glucose assessed with statistical parametric mapping. Neuroimage. 7:1998;176-184.
126. R.E. Powers, Neurobiology of aging, in: C.E. Coffey, J.L. Cummings (Eds.), Textbook of Geriatric Neuropsychiatry, American Psychiatric Press, Washington, DC, 1994, pp. 36-69.
127. Ramasubbu R., Flint A., Brown G., Awad G., Kennedy S. Diminished serotonin-mediated prolactin responses in nondepressed stroke patients compared with healthy normal subjects. Stroke. 29:1998;1293-1298.
128. Reimherr F.W., Wood D.R., Byerley B., Brainard J., Grosser B.I. Characteristics of responders to fluoxetine. Psychopharmacol. Bull. 20:1984;70-72.
129. Robinson D.S. Changes in monoamine oxidase and monoamines with human development and aging. Fed. Proc. 34:1975;103-107.
130. Robson L., Gower A.J., Kendall D.A., Marsden C.A. Age-related behavioural, neurochemical and radioligand binding changes in the central 5-HT system of Sprague-Dawley rats. Psychopharmacology. 113:1993;274-281.
131. Roose S.P., Glassman A.H., Attia E., Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am. J. Psychiatry. 151:1994;1735-1739.
132. Roose S.P., Suthers K.M. Antidepressant response in late-life depression. J. Clin. Psychiatry. 59:1998;4-8.
133. 18F ]altanserin and positron emission tomographic imaging Psychiatric Res.: Neuroimaging. 68:1996;11-22.
134. Rubin E., Sackeim H.A., Prohovnik I., Moeller J.R., Schnur D.B., Mukherjee S. Regional cerebral blood flow in mood disorders: IV. Comparison of mania and depression. Psychiatric Res.: Neuroimaging. 61:1995;1-10.
135. Ryan N.D., Varma D. Child and adolescent mood disorders - experience with serotonin-based therapies. Biol. Psychiatry. 44:1998;336-340.
136. Sackeim H.A., Prudic J., Devanand D.P., Kiersky J.E., Fitzsimons L., Moody B.J., McElhiney M.C., Coleman E.A., Setttembrino J.M. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. New Engl. J. Med. 328:1993;839-846.
137. H.A. Sackeim, S.H. Lisanby, M.S. Nobler, R.L. Van Heertum, R.L. DelaPaz, B. Mensh, MRI hyperintensities in major depression: the meaning of encephalomalacia, in: C. Andrade (Ed.), Progress in Psychiatry, Oxford Univ. Press, New York, in press.
138. H.A. Sackeim, I. Prohovnik, Brain imaging studies of depressive disorders, in: J.J. Mann, D. Kupfer (Eds.), The Biology of Depressive Disorders. Part A: A Systems Perspective, Plenum, New York, 1993, pp. 205-258.
139. Sackeim H.A., Prohovnik I., Moeller J.R., Brown R.F., Apter S., Prudic J., Mukherjee S. Regional cerebral blood flow in mood disorders: I. Comparison of major depressives and normal controls. Arch. Gen. Psychiatry. 47:1990;60-70.
140. Sackeim H.A., Prohovnik I., Moeller J.R., Mayeux R., Stern Y., Devanand D. Regional cerebral blood flow in mood disorders: II. Comparison of major depression and Alzheimer's disease. J. Nucl. Med. 34:1993;1090-1101.
141. Sallee F.R., Koran L.M., Pallanti S., Carson S.W., Sethuraman G. Intravenous clomipramine challenge in obsessive-compulsive disorder: predicting response to oral therapy at eight weeks. Biol. Psychiatry. 44:1998;220-227.
142. L.S. Schneider, C.F. Reynolds, B.D. Lebowitz, A.J. Friedhoff (Eds.), Diagnosis and Treatment of Depression in Late Life, American Psychiatric Press, Washington, DC, 1994.
143. Seifritz E., Baumann P., Muller M.J., Annen O., Amey M., Hemmeter U., Hatzinger M., Chardon F., Holsboer-Trachsler E. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. Neuropsychopharmacology. 14:1996;253-263.
144. 3H ]imipramine binding in aged human brain J. Neurochem. 45:1985;1382-1389.
145. Shih J.C., Young H. The alteration of serotonin binding sites in aged human brain. Life Sci. 23:1978;1441-1448.
146. Smith D.F., Poulsen P.H., Ishizu K., Sakoh M., Hansen S.B., Gee A.D., Bender D., Gjedde A. Quantitative PET analysis of regional cerebral blood flow and glucose and oxygen metabolism in response to fenfluramine in living porcine brain. J. Neurosci. Methods. 86:1998;17-23.
147. Soares J.C., Mann J.J. The functional neuroanatomy of mood disorders. J. Psychiatr. Res. 31:1997;393-432.
148. Spreux-Varoquaux O., Gailledreau J., Banier B., Bothua D., Plas J., Chevalier J.F., Advenier C., Pays M., Brion S. Initial increase of plasma serotonin: a biological predictor for the antidepressant response to clomipramine? Biol. Psychiatry. 40:1996;465-473.
149. Staley J.K., Malison R.T., Innis R.B. Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression. Biol. Psychiatry. 44:1998;534-549.
150. Tignol J., Stoker M.J., Dunbar G.C. Paroxetine in the treatment of melancholia and severe depression. Int. Clin. Psychopharmacol. 7:1992;91-94.
151. Tollefson G.D., Holman S.L. Analysis of the Hamilton depression rating scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression. Int. Clin. Psychopharmacol. 8:1993;253-259.
152. Underwood M.D., Bakalian M.J., Arango V., Smith R.W., Mann J.J. Regulation of cortical blood flow by the dorsal raphe nucleus: topographic organization of cerebrovascular regulatory regions. J. Cereb. Blood Flow Metab. 12:1992;664-673.
153. Upadhyaya A.K., Abou-Saleh M.T., Wilson K., Grime S.J., Critchley M. A study of depression in old age using single-photon emission computerised tomography. Br. J. Psychiatry. 157:1990;76-81.
154. Van Bockstaele E.J., Pickel P.M. Ultrastructure of serotonin-immunoreactive terminals in the core and shell of the rat nucleus accumbens: cellular substrates for interactions with catecholamine afferents. J. Comp. Neurol. 334:1993;603-617.
155. 2 and dopamine D2 receptor availability in healthy human subjects. Life Sci. 56:1995;PL249-PL253.
156. 11C ]-methyl)-2-Br.-LSD Synapse. 1:1987;393-398.
157. Wong D.F., Wagner H.N., Dannals R.F., Links J.M., Frost J.J., Ravert H.T., Wilson A.A., Rosenbaum A.E., Gjedde A., Douglass K.H., Petronis J., Folstein M., Toung J., Burns H., Kuhar M. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science. 226:1984;1393-1396.
158. 1A receptor agonist ipsapirone on the local cerebral glucose utilization of the rat hippocampus. Brain Res. 436:1987;283-290.
159. Yamaguchi T., Yamagata A. Serotonergic ligand binding in aging brain of experimental animals. Neurochem. Res. 16:1991;469-473.
160. Yoshii F., Barker W.W., Chang J.Y., Loewenstein D., Apicella A., Smith D., Boothe T., Ginsberg M.D., Pascal S., Duara R. Sensitivity of cerebral glucose metabolism to age, gender, brain volume, brain atrophy, and cerebrovascular risk factors. J. Cereb. Blood Flow Metab. 8:1988;654-661.